Status:

COMPLETED

The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer

Lead Sponsor:

Ferring Pharmaceuticals

Conditions:

Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this trial was to select a dose of degarelix (FE 200486). Three groups of patients were treated for six months on different doses. The patients had blood samples taken and measured for ...

Detailed Description

Degarelix was not FDA regulated at the time of the trial. After completion of the trial degarelix has been approved by the FDA and is thus an FDA regulated intervention.

Eligibility Criteria

Inclusion

  • Signed informed consent before any trial related activity
  • Proven prostate cancer with a need for endocrine treatment
  • Testosterone level within the normal range for the age

Exclusion

  • Previous or current hormonal treatment of prostate cancer
  • Candidate for prostatectomy or radiotherapy
  • History of severe asthma, anaphylactic reactions or Quincke's Oedema
  • Hypersensitivity towards any component of FE200486
  • Cancer disease within the last ten years except for prostate cancer and some skin cancers
  • Presenting with significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, haematological, dermatological or infectious disorder. In addition any other condition such as excessive alcohol or drug abuse that may interfere with trial participation or influence the conclusion of the trial as judged by the investigator
  • Mental incapacity or language barrier
  • Having received an investigational product within the last 12 weeks preceding the trial
  • Previous participation in this trial

Key Trial Info

Start Date :

March 1 2001

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2002

Estimated Enrollment :

129 Patients enrolled

Trial Details

Trial ID

NCT00819247

Start Date

March 1 2001

End Date

August 1 2002

Last Update

November 9 2023

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Ayr Hospital

Ayr, United Kingdom

2

Bristol Royal Infirmary

Bristol, United Kingdom

3

Southmead Hospital

Bristol, United Kingdom

4

St. Richards Hospital

Chichester, United Kingdom

The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer | DecenTrialz